Share Market Newspaper

Creative Biolabs Leads the Charge Against SARS-CoV-2

 Breaking News
  • No posts were found

Creative Biolabs Leads the Charge Against SARS-CoV-2

October 27
18:15 2023
Over the years, Creative Biolabs has amassed profound expertise in SARS-CoV-2 detection, vaccine development, and drug discovery amid the virus’s relentless global onslaught.

New York, USA – October 27, 2023 – Since the emergence of the COVID-19 pandemic in late 2019, Creative Biolabs has emerged as a stalwart force against the unprecedented threat posed by the SARS-CoV-2 virus.

“Five years have passed since the discovery of the novel coronavirus, yet SARS-CoV-2 refuses to wane; it persists,” declared an expert at Creative Biolabs. “In the face of this lingering menace, our commitment to researching this novel coronavirus remains unwavering.”

In the battle against SARS-CoV-2, a comprehensive strategy involving preventive vaccines and therapeutic drugs is imperative. Creative Biolabs offers a robust vaccine development platform, including the cutting-edge formulation optimization platform for SARS-CoV-2 vaccine, along with services for vaccine analysis and identification.

Creative Biolabs supports the development of vaccines for SARS-CoV-2 and emerging infectious diseases, offering expertise in various stages, including:

* Recombinant Subunit Vaccine

* SARS-CoV-2 DNA Vaccine

* mRNA Vaccine

A pivotal breakthrough in Creative Biolabs’ SARS-CoV-2 research is the development of neutralizing antibodies, offering key specificity in defense against viral infections. “Neutralizing antibodies, specifically those targeting the S-protein of SARS-CoV-2, play a vital role by preventing viral invasion and conferring passive immunity against the disease,” explained the expert.

Creative Biolabs focuses on CR3022, CD4, and glycoprotein in the development of these crucial neutralizing antibodies against SARS-CoV-2, aiding global clients in advancing the discovery of anti-SARS-CoV-2 drugs.

Notably, the company emphasizes glycoprotein targeting for SARS-CoV-2 antibody discovery, drawing inspiration from the success of monoclonal antibody mAb114 against the glycoprotein of the Ebola virus.

In addition to its work in vaccine development and anti-viral drug discovery, Creative Biolabs offers specialized virus detection services, including the veterinary-use SARS-CoV-2 detection service. Given the potential transmission of SARS-CoV-2 in animals, Creative Biolabs’ animal detection kits serve as a crucial control mechanism, emphasizing the importance of understanding the virus’s interactions with various species.

“Our in vitro diagnostic kits for animal detection are adept at detecting antibodies against SARS-CoV-2 nucleocapsid in the serum or plasma of diverse animals, including cats and dogs,” announced the expert. “Our proactive approach to exploring potential animal hosts and transmission routes underscores our dedication to outmaneuvering the virus.”

Creative Biolabs’ comprehensive services span the entire spectrum of antiviral efforts. From cutting-edge computational modeling and vaccine formulation optimization to the development of neutralizing antibodies, Creative Biolabs provides unparalleled technical support and innovative solutions to researchers worldwide.

For more services offered by Creative Biolabs, please visit

About Creative Biolabs

In the relentless fight against the SARS-CoV-2 virus, Creative Biolabs, a pioneering laboratory service provider, stands at the vanguard, offering groundbreaking solutions to researchers worldwide. Committed to expanding scientific knowledge and providing innovative solutions, Creative Biolabs continues to lead the charge against complex global disease challenges.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States